NUCLEIX
LIVE

Serial Number

97848574

Owner

Nucleix Limited

Attorney

Jennifer Sheehan Anderson

Filing Date

Mar 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

NUCLEIX Trademark

Serial Number: 97848574 • Registration: 7575478

NUCLEIX is a trademark filed by Nucleix Limited on March 21, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Nucleix Limited (5 trademarks)

Pekeris 3
Rehovot 7670203 , IL

Entity Type: 03

Trademark Details

Filing Date

March 21, 2023

Registration Date

November 26, 2024

Published for Opposition

September 24, 2024

Goods & Services

Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic assay kits comprised of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD) autoimmune disease and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease in the field of cancer detection or detection, detection of chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; diagnostic reagents for medical purposes

Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use

Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease; providing cancer screening services; providing medical screening services for chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease

Medical apparatus for medical diagnostic testing in the fields of cancer or chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease

Pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 24, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 24, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 4, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 19, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 19, 2024 CRFA
ASSIGNED TO LIE
Aug 19, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 4, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2023 NWOS
NEW APPLICATION ENTERED
Mar 24, 2023 NWAP